Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011; Massachusetts Medical Society; Volume: 364; Issue: 6 Linguagem: Inglês
10.1056/nejmoa1009290
ISSN1533-4406
AutoresJames C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg,
Tópico(s)Gestational Trophoblastic Disease Studies
ResumoEverolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study.
Referência(s)